Prescribing and Administration of Analgesia within Maternity

Similar documents
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY

BJF Acute Pain Team Formulary Group

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

PACKAGE INSERT. The other ingredients are: sodium acetate and water for injection.

Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain

PART 1.B SPC, LABELLING AND PACKAGE LEAFLET

SUMMARY OF PRODUCT CHARACTERISTICS ENGLISH Dolol 50 mg capsules

Guidelines on the Administration of Paracetamol in Children

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet

SUMMARY OF PRODUCT CHARACTERISTICS

XTRAM. Composition Xtram 50 mg capsule Each capsule contains Tramadol HCl 50 mg

Migraleve, Migraleve Pink and Migraleve Yellow Product Information

Package leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate

Summary of Product Characteristics

Fact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII

Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days (4)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PRESCRIBING ALERT

Switching Tramacet to paracetamol alone or paracetamol and codeine

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Clinical Guideline. Guidelines for the use of opioid analgesics in the management of acute pain in adults

PARACOD Tablets (Paracetamol + Codeine phosphate)

patient group direction

Contributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.

GUIDELINE FOR THE POST OPERATIVE MANAGEMENT OF WOMEN WHO HAVE RECEIVED INTRATHECAL OR EPIDURAL OPIOID ANALGESIA FOR CAESAREAN SECTION

Guideline for the Post Operative Management of Women who have received Intrathecal or Epidural Opioid Analgesia for Caesarean Section

enough to require an opioid analgesic and for which alternative treatments are inadequate. (1)

Update to Product Monograph

BACKGROUND Measuring renal function :

September 5 9, 2017 The Cosmopolitan of Las Vegas Program Guide. Program guide is sponsored by

Berkshire West Area Prescribing Committee Guidance

Primary care review of Tramadol Prescribing

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Analgesia in patients with impaired renal function Formulary Guidance

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

CONSUMER MEDICINE INFORMATION

Asthma in Pregnancy, Labour and Postnatal Guidelines

INTRODUCING. Potential Monotherapy Option 5 Provided in Convenient Vials 1 Reimbursable J-Code Available 3

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013

Post-operative Analgesia for Caesarean Section

SUMMARY OF PRODUCT CHARACTERISTICS

TRAMADOL hydrochloride extended-release tablets for oral use, C IV Initial U.S. Approval: 1995

Pain relief to take home after your surgery

SUMMARY OF PRODUCT CHARACTERISTICS

Facts About BELBUCA (buprenorphine) Buccal Film

OAA Survey 156: Current prescribing practices for post-operative analgesia following emergency and elective LSCS

Page 1 of 43. TRAMADOL hydrochloride extended-release tablets for oral use, C IV Initial U.S. Approval: 1995

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery

Day care adenotonsillectomy in sleep apnoea

Frequently Asked Questions

The safety concerns defined with the reference product apply to Buprenorphine-Naloxone 2/0.5 mg, 8/2 mg, sublingual tablets.

Summary of risk management plan for Dzuveo (Sufentanil (as citrate))

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults. Consultation Group: See Page 5

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS

Package leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride

NUCYNTA ER (tapentadol) extended-release tablets for oral use C-II Initial U.S. Approval: 2008

SUMMARY OF PRODUCT CHARACTERISTICS

Consumer Medicine Information

Part VI: Summary of the risk management plan by product

Elements for a Public Summary Overview of disease epidemiology

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

Probuphine. (buprenorphine implant) New Product Slideshow

HIGHLIGHTS OF PRESCRIBING INFORMATION

Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre.

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS

PAIN PODCAST SHOW NOTES:

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

INTRAVENOUS HYDRALAZINE POLICY

APADAZ (benzhydrocodone and acetaminophen) tablets, for oral use, CII Initial U.S. Approval: 1982

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

Neuropathic Pain Treatment Guidelines

NEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 50 mg of tramadol hydrochloride.

RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act

CHEMMART TRAMADOL SR TABLETS. (1RS,2RS)-2-[(dimethylamino)methyl)]-1-(3-methoxyphenyl)cyclohexanol hydrochloride.

PRODUCT INFORMATION ZYDOL

APO-TRAMADOL CAPSULES. (1RS,2RS)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol hydrochloride

CHEMMART TRAMADOL CAPSULES. (1RS,2RS)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol hydrochloride

Trust Guideline for the Management of Patient Controlled Analgesia (PCA) in Adults

EXTENDED RELEASE OPIOID DRUGS

RoxyBond is the first and only FDA-approved immediate-release opioid medication with abuse-deterrent claims in its approved labeling

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CALPOL T. Tramadol Hydrochloride and Acetaminophen Tablets USP

Annex C. (variation to nationally authorised medicinal products)

POSTOPERATIVE PAIN RELIEF

TRAMAL SR Sustained Release Tablets

HIGHLIGHTS OF PRESCRIBING INFORMATION

Codeine and Paracetamol in Paediatric use, an Update 5 th October 2013

Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers

Press Release PP-US-MB /17

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017

facilities that prescribe for inpatient use), patient and prescriber enrollment is not required.

21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Initial U.S. Approval: 1995

Transcription:

Prescribing and Administration of Analgesia within Maternity CONTENTS Introduction and Who The Guideline Applies To... 2 UHL Paracetamol Prescribing Guideline... 2 Oral dosing... 2 Intravenous dosing... 2 Risk factors for hepatotoxicity... 3 Dose adjustment of Paracetamol in adults... 3 Calculating Dosage of Paracetamol... 4 Post Operative Prescribing... 5 In theatre at the end of procedure if no contraindications... 5 Regular Prescribing in hospital... 5 As Required Prescriptions in Hospital... 5 If Diclofenac prescribed:... 5 If Diclofenac contraindicated:... 6 If Dihydrocodeine contraindicated:... 6 DISCHARGE (TTO) ANALGESIA... 6 Alternatives... 6 Patients weighing <39.9kg... 6 Multiple drug allergies or Complex Pain... 6 DEVELOPMENT AND APPROVAL RECORD FOR THIS DOCUMENT... 9 Post Caesarean Section Analgesia V4 Page 1 of 9

INTRODUCTION AND WHO THE GUIDELINE APPLIES TO This guideline applies to midwifery, medical, anaesthetic and pharmacy staff working within the Maternity Unit who prescribe or administer analgesic medication. It incorporates the Trust guidance on Paracetamol prescribing as well as what to prescribe and administer to women in the antenatal / postnatal period and to those who have had a caesarean section. UHL PARACETAMOL PRESCRIBING GUIDELINE Paracetamol can cause liver damage in patients who have certain identifiable risks factors and therefore therapeutic dosing may need to be reduced. Intravenous therapy is shown to have a higher peak plasma level than oral and patients with a low body weight <50kg will need a reduced dose regardless of whether risk factors are present or not. The aim of this guideline is to provide safe dosing for oral and intravenous Paracetamol in patients aged 16 years or more treated within the UHL Maternity Service. Separate guidance exists for children. NB: When daily maximum dose of Paracetamol has been exceeded by a pregnant patient, whether accidentally or intentionally, treatment should be considered even when maternal Paracetamol levels do not reach treatment threshold. This is because the fetal liver is immature, and fetal hepatic toxicity can occur at lower levels than the mother s. Please discuss with Consultant Obstetrician in all cases where dose has been exceeded. ORAL DOSING Paracetamol has a narrow therapeutic index. Toxicity can occur when the patient has identifiable risk factors for liver toxicity (see section 5). There is no formal guidance for adjusting oral dosing and so, to minimise risk of liver damage for patients with risk factors, a maximum daily dose of 75mg/kg has been agreed. The doses have been rounded to the nearest 500mg dose to help with administration. Patients who require a dosage adjustment must be advised that this is lower than the maximum dose of paracetamol recommended in package inserts. INTRAVENOUS DOSING Intravenous administration of Paracetamol results in higher peak plasma levels than the same dose given orally. The product license specifies that the standard maximum daily dose of 4g daily must be decreased in patients with a body weight 50kg or in those with risk factors for toxicity. The dosing interval needs to be increased in patients with severe renal impairment. (4) Post Caesarean Section Analgesia V4 Page 2 of 9

RISK FACTORS FOR HEPATOTOXICITY The following are risk factors for hepatotoxicity: Malnourished patients, with nutritional deficiency and/or chronic debilitating illness and therefore likely to be glutathione deplete: acute (patients not eating for a few days) or chronic starvation eating disorders (anorexia or bulimia) cystic fibrosis AIDS cachexia alcoholism Hepatitis C Hepatic enzyme induction or evidence of on-going liver injury e.g. long term treatment with liver enzyme-inducing drugs such as Carbamazepine, Phenobarbital, Phenytoin, Primidone, Rifampicin, Rifabutin, Efavirenz, Nevirapine, St John's Wort, Regular consumption of ethanol in excess of recommended amounts, particularly if nutritionally compromised. DOSE ADJUSTMENT OF PARACETAMOL IN ADULTS Record booking weight on drug chart. Where dose reduction has occurred, consider re-weighing the woman once she is mobile after delivery. Paracetamol dose can then adjusted if necessary. Assess the patient for risk factors for toxicity. If risk factors are present REDUCE the total daily dose. Prescribe the oral dose in multiples of 500mg of Paracetamol. Do not exceed four doses of Paracetamol in 24 hours For IV dosing, see table below Post Caesarean Section Analgesia V4 Page 3 of 9

CALCULATING DOSAGE OF PARACETAMOL The following charts guide safe dosing levels for adults >16 years. Dose of ORAL Paracetamol for ALL adults WITHOUT risk factors 500mg 1g every 4-6 hours, maximum 4g daily Dose of ORAL Paracetamol for adults WITH risk factors 30-39kg Dose reduction is required. Discuss with senior clinician / pharmacy 40-50kg 500mg every 4-6hours. Maximum 2g / 24 hours >50.1kg 500mg 1g every 4-6 hours. Maximum 4g / 24 hours Dose of IV Paracetamol for adults 33kg with or without risk factors 33kg - 50kg >50kg WITH risk factors >50kg WITHOUT risk factors egfr <30ml / min 15mg / kg every 4-6 hours. Maximum 2g / 24 hours 15mg / kg every 4-6hours. Maximum 3g / 24 hours 750mg every 4-6 hours. Maximum 3g / 24 hours 1g every 4-6 hours. Maximum 4g / 24 hours Dose as above according to weight and risk factors BUT increase dosing interval to 6 hours. Post Caesarean Section Analgesia V4 Page 4 of 9

POST OPERATIVE PRESCRIBING IN THEATRE AT THE END OF PROCEDURE IF NO CONTRAINDICATIONS All Adults 18 years and over: 100mg Diclofenac sodium PR Children aged under 18 years (as per BNF): 1mg/kg per dose, maximum 50mg per dose of Diclofenac Sodium PR REGULAR PRESCRIBING IN HOSPITAL Paracetamol 1g orally 6hrly/QDS (maximum of 4g in 24 hours). Dose should be adjusted as above if required. Diclofenac 50mg orally 8 hourly / TDS with the first dose following theatre prescribed for administration on the drug round AFTER a minimum of 16 hours from the PR dose in theatre. This will ensure a maximum intake of 150mg in 24 hours. Children up to 18 years can be given 1mg/kg per dose of Diclofenac orally (in multiples of 25mg) up to a maximum of 50mg per dose (150mg per 24 hours). The first dose following theatre should be prescribed for administration on the drug round AFTER a minimum of 16 hours from the PR dose in theatre. IF DICLOFENAC CONTRAINDICATED: Tramadol 50mg orally 6 hrly/qds may be prescribed regularly for patients who cannot have Diclofenac. See Appendix 1 for contraindications. AS REQUIRED PRESCRIPTIONS IN HOSPITAL IF DICLOFENAC PRESCRIBED: Dihydrocodeine 30mg orally 4hrly Oramorph (Morphine Sulfate solution) 20mg orally 2hrly NB: 1st dose to be given minimum 4 hours after Diamorphine intrathecal/ epidural. Cyclizine 50mg PO/IV/IM 8hrly IV Paracetamol as single dose at the discretion of the Anaesthetist. This should be written on the front of the UHL maternity prescription chart and a note made on the regular prescription of Paracetamol to avoid overdosing. Post Caesarean Section Analgesia V4 Page 5 of 9

For women <50kg, please note the dose is 15mg/kg with a maximum dosage of 3g / 24hours (see table on page 4 for further details). IF DICLOFENAC CONTRAINDICATED: Where women cannot take Diclofenac, in addition to regular Tramadol, Dihydrocodeine, Oramorph and Cyclizine can be prescribed in the PRN section of the drug chart. IF DIHYDROCODEINE CONTRAINDICATED: If Dihydrocodeine is not tolerated, prescribe tramadol 50mg orally / IV 6hrly / QDS. DISCHARGE (TTO) ANALGESIA Dihydrocodeine 30mg PO / 4hrly / PRN unless contraindicated Diclofenac 50mg PO / TDS / PRN, unless contraindicated Paracetamol 1g PO / QDS / PRN (maximum dose 4 g in 24 hours). For dose adjustments, see paracetamol specific section above. Please note Paracetamol is not usually provided as a TTO, the patient is advised to obtain over the counter at a chemist s/pharmacy outside hospital. ALTERNATIVES If both Diclofenac and Dihydrocodeine are contraindicated then the following may be prescribed as an alternative: Tramadol 50mg QDS (up to 12 doses) PATIENTS WEIGHING <39.9KG It is recommended that patients are weighed prior to discharge to confirm that they are below this weight. Under these rare circumstances, an individualised care plan should be made in conjunction with a senior clinician and pharmacist, ideally antenatally. MULTIPLE DRUG ALLERGIES OR COMPLEX PAIN In patients with complex pain needs (usually related to pre-existing conditions), an individualised care plan should be made, ideally antenatally. Post Caesarean Section Analgesia V4 Page 6 of 9

APPENDIX 1 CONTRA-INDICATIONS FOR ALL OPIOIDS: Acute respiratory depression; comatose patients; head injury (opioid analgesics interfere with pupillary responses vital for neurological assessment); raised intracranial pressure (opioid analgesics interfere with pupillary responses vital for neurological assessment); risk of paralytic ileus FOR TRAMADOL HYDROCHLORIDE: Acute intoxication with alcohol; acute intoxication with analgesics; acute intoxication with hypnotics; acute intoxication with opioids; not suitable for narcotic withdrawal treatment; uncontrolled epilepsy CAUTIONS FOR ALL OPIOIDS: Adrenocortical insufficiency (reduced dose is recommended); asthma (avoid during an acute attack); convulsive disorders; debilitated patients (reduced dose is recommended) (in adults); diseases of the biliary tract; elderly (reduced dose is recommended) (in adults); hypotension; hypothyroidism (reduced dose is recommended); impaired respiratory function (avoid in chronic obstructive pulmonary disease); inflammatory bowel disorders; myasthenia gravis; obstructive bowel disorders; prostatic hypertrophy (in adults); shock; urethral stenosis (in adults) DEPENDENCE Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. FOR TRAMADOL HYDROCHLORIDE: Excessive bronchial secretions; history of epilepsy use tramadol only if compelling reasons; impaired consciousness; not suitable as a substitute in opioid-dependent patients; not suitable in some types of general anaesthesia; susceptibility to seizures use tramadol only if compelling reasons Post Caesarean Section Analgesia V4 Page 7 of 9

DRUG INTERACTIONS Tramadol should not be combined with MAO inhibitors (see section 4.3). In patients treated with MAO inhibitors in the 14 days prior to the use of the opioid pethidine, life threatening interactions on the central nervous system, respiratory and cardiovascular function have been observed. The same interactions with MAO inhibitors cannot be ruled out during treatment with Tramadol. The combination with mixed agonist/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) and tramadol is not advisable, because the analgesic effect of a pure agonist may be theoretically reduced in such circumstances. Tramadol can induce convulsions and increase the potential for selective serotonin re-uptake inhibitors, (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic anti-depressants, anti-psychotics and other seizure threshold lowering medicinal products (such as bupropion, mirtazapine, tetrahydrocannabinol) to cause convulsions. Concomitant therapeutic use of tramadol and serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAO inhibitors (see section 4.3), tricyclic antidepressants and mirtazapine may cause serotonin toxicity. Signs of serotonin syndrome may be for example confusion, agitation, fever, sweating, ataxia, hyperreflexia, myoclonus and diarrhoea. Serotonin syndrome is likely when one of the following is observed: Spontaneous clonus Inducible or ocular clonus with agitation or diaphoresis Tremor and hyperreflexia Hypertonia and body temperature > 38 o C and inducible or ocular clonus. Withdrawal of the serotoninergic medicinal products usually brings about a rapid improvement. Treatment depends on the nature and severity of the symptoms. Caution should be exercised during concomitant treatment with tramadol and coumarin derivatives (e.g. warfarin) due to reports of increased INR with major bleeding and ecchymoses in some patients. Post Caesarean Section Analgesia V4 Page 8 of 9

DEVELOPMENT AND APPROVAL RECORD FOR THIS DOCUMENT Author / Lead Officer: C Elton and J Qualie Job Title: Consultant Anaesthetist and Pharmacist Reviewed by: Multi-Disciplinary Delivery Suite Forum Group Approved by: Maternity Services Governance Group Date Approved: 11.03.14 19.09.18 REVIEW RECORD Date Issue Reviewed By Description Of Changes (If Any) Number March 2014 V2 As above Unified cross site. Divided as per booking weight > 50kg or < 50kg. Change to Tramadol dose September 2016 V3 Clarification on Paracetamol dosage. Guidance added for use in all areas within Maternity September 2018 V4 As above Updated to come into line with UHL Paracetamol Policy and other types of medication updated. Format changed DISTRIBUTION RECORD: Date Name Dept Received 17.03.14 All Anaesthetists, Obstetricians and Maternity Midwives 10.16 All Anaesthetists, Obstetricians and Maternity Midwives 9 18 All Anaesthetists, Obstetricians and Midwives Maternity Post Caesarean Section Analgesia V4 Page 9 of 9